ÐÂÎÅ×ÊѶ
ÎÄÏ××ÛÊö£º´øÄãÁ˽âÍâÃÚÌåÔÚºôÎüϵͳ¼²²¡ÖеĴó×÷Ϊ
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÐ¡¸ß
- À´Ô´£º
¡¾¸ÅÒªÃèÊö¡¿ºôÎüϵͳ¼²²¡Ö÷Òª°üÀ¨ÂýÐÔ×èÈûÐԷβ¡£¨COPD£©¡¢Ïø´¡¢ºôÎüµÀ¸ÐȾ¡¢·Î½áºË¡¢¼äÖÊÐԷβ¡¡¢·Î°©µÈ£¬ÆäÖзΰ©ÔÚÈ«ÇòµÄ·¢²¡ÂʺÍËÀÍöÂʾù¾ÓÊ×룬¶øÖÁ½ñÈÔÈ»ÔÚÈ«Çò±¬·¢ÂûÑÓµÄCOVID-19µ¼ÖÂÁËÖØ´óµÄÈËÔ±ËÀÍöºÍ¾¼Ã¸ºµ£¡£
ÎÄÏ××ÛÊö£º´øÄãÁ˽âÍâÃÚÌåÔÚºôÎüϵͳ¼²²¡ÖеĴó×÷Ϊ
¡¾¸ÅÒªÃèÊö¡¿ºôÎüϵͳ¼²²¡Ö÷Òª°üÀ¨ÂýÐÔ×èÈûÐԷβ¡£¨COPD£©¡¢Ïø´¡¢ºôÎüµÀ¸ÐȾ¡¢·Î½áºË¡¢¼äÖÊÐԷβ¡¡¢·Î°©µÈ£¬ÆäÖзΰ©ÔÚÈ«ÇòµÄ·¢²¡ÂʺÍËÀÍöÂʾù¾ÓÊ×룬¶øÖÁ½ñÈÔÈ»ÔÚÈ«Çò±¬·¢ÂûÑÓµÄCOVID-19µ¼ÖÂÁËÖØ´óµÄÈËÔ±ËÀÍöºÍ¾¼Ã¸ºµ£¡£
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÐ¡¸ß
- À´Ô´£º
- ·¢²¼Ê±¼ä£º2022-04-25 13:32
- ·ÃÎÊÁ¿£º
ºôÎüϵͳ¼²²¡Ö÷Òª°üÀ¨ÂýÐÔ×èÈûÐԷβ¡£¨COPD£©¡¢Ïø´¡¢ºôÎüµÀ¸ÐȾ¡¢·Î½áºË¡¢¼äÖÊÐԷβ¡¡¢·Î°©µÈ£¬ÆäÖзΰ©ÔÚÈ«ÇòµÄ·¢²¡ÂʺÍËÀÍöÂʾù¾ÓÊ×룬¶øÖÁ½ñÈÔÈ»ÔÚÈ«Çò±¬·¢ÂûÑÓµÄCOVID-19µ¼ÖÂÁËÖØ´óµÄÈËÔ±ËÀÍöºÍ¾¼Ã¸ºµ£¡£ËùÒÔ£¬ÉîÈëÑо¿ºôÎüϵͳ¼²²¡µÄ·¢²¡»úÖƽ«Îª¼²²¡µÄÓÐЧ·ÀÖÎÌṩ²ßÂÔ¡£ºôÎüϵͳ¼²²¡µÄ·¢ÉúºÍ·¢Õ¹Í¨³£È¡¾öÓÚ»·¾³Ñ¹Á¦£¨ÎüÈëµÄÎÛȾÎï¡¢²¡Ô¾ú¸ÐȾ£©¡¢ÃâÒßϵͳ£¨¶àÖÖÃâÒßϸ°ûºÍϸ°ûÒò×Ó£©¡¢ÒÅ´«Çý¶¯ÒòËØÖ®¼äµÄÏ໥е÷¡¢Ï໥×÷ÓÃÒÔ¼°¶àÖÖÀàÐ͵ķÎϸ°ûÖ®¼äµÄ½»Á÷£¬Í¬Ê±ÍâÃÚÌåÔڷβ¿Î¢»·¾³Öз¢»ÓÖØÒª×÷Ó㬲¢¿ÉÒÔ×÷Ϊ¶àÖַβ¿¼²²¡µÄ±êÖ¾Îï1¡£ÄÇôÍâÃÚÌåÔÚºôÎüϵͳ¼²²¡ÖÐÖ÷Òª²ÎÓëÄÄЩ·½ÃæÄØ£¿ÔõôÑùϵͳÐÔÑо¿ÍâÃÚÌåÔÚºôÎüϵͳÏà¹Ø¼²²¡·¢Éú»úÖÆÖеŦÄÜÄØ£¿½ñÌ컪ӯÊÓ½Çͨ¹ý3ƪÍâÃÚÌåÓëºôÎüϵͳ¼²²¡»úÖÆÑо¿µÄ°¸Àý£¬Îª·ÛË¿Ãǽâ¶ÁÍâÃÚÌåÔÚºôÎüϵͳ¼²²¡ÕïÁÆÖеÄÑо¿½øÕ¹ºÍÑо¿Ë¼Â·¡£
| °¸ÀýÒ» ÆøµÀÉÏƤϸ°ûÍâÃÚÌå´Ù½øÊ÷ͻ״ϸ°û½éµ¼µÄTϸ°û·´Ó¦Òý·¢¹ýÃôÐÔÏø´
±¾Ñо¿ÓÚ2021Äê·¢±íÔÚJ Allergy Clin ImmunolÔÓÖ¾ (IF=10.793)2¡£Ñо¿ÕßÊ×ÏÈ·¢ÏÖ·¿³¾òý£¨HDM£©´Ì¼¤ºóµÄСÊóÆøµÀÉÏƤϸ°û£¨AEC£¬airway epithelial cell£©·ÖÃÚµÄÍâÃÚÌ壨HDM-AECs-EXO£©¿ÉÒÔÓÕµ¼·Î²¿Ê÷ͻ״ϸ°û£¨DC£¬dendritic cell£©»ýÀÛµ¼ÖÂÕý³£Ð¡Êó¹ýÃôÐÔÏø´£¬²¢ÇÒ¹ý¼ÌEXOÓÕµ¼²úÉúµÄDC¾Í¿ÉÒÔÔì³ÉÕý³£Ð¡Êó¹ýÃôÐÔÏø´µÄ·¢Éú£¨Í¼1A¡¢B£©¡£
Ëæºó£¬Í¨¹ýµ°°×ÖÊ×éѧ·¢ÏÖÏà½ÏÓÚ¶ÔÕÕ×飨PBS´¦ÀíµÄСÊóAEC-EXO£©£¬ÊµÑé×éHDM-AECs-EXO£¨HDMÓÕµ¼µÄÏø´Ð¡ÊóµÄAEC-EXO£©Öк¬Óиü¶àµÄCNTN-1£¨contactin-1£¬Ò»ÖÖϸ°û𤸽·Ö×Ó£©µ°°×£¬²¢Í¨¹ýWBºÍÃâÒßÓ«¹âÑéÖ¤ÁËCNTN-1µ°°×µÄ¸ß±í´ï£¨Í¼1C£©¡£½Ó×Å£¬Í¨¹ý¶ÔСÊóβ¾²Âö×¢ÉäNC-siRNAºÍCNTN-1-siRNA·¢ÏÖCNTN-1-siRNA¿ÉÒÖÖÆDC³ÉÊìºÍDCÑÇȺÔÚ·ÎÖеĻýÀÛ£¬Ôö¼ÓСÊóѪÇåIgEºÍ·Î×éÖ¯ÁѽâÒºÖÐϸ°ûÒò×ÓIL-4, IL-5, IL-13, IL-17A ˮƽ£¬Ö¤Ã÷ÁËCNTN1·¢»Ó¹ýÃôÐÔÆøµÀµÄ´ÙÑ××÷Óã¨Í¼1D£©¡£
´ËÍ⣬ÓÐÑо¿ÒѾ±íÃ÷CNTN1¿ÉÒÔ×÷ΪNotchµÄ¹¦ÄÜÐÔÅäÌ壬×÷Õßͨ¹ýÃâÒß¹²³Áµí·¢ÏÖÁËCNTN1¿ÉÒÔÓë Notch2½áºÏ£¨Í¼1E£©£¬ÒÖÖÆNotchÐźÅͨ·ºó£¬CNTN1ÔÚÆøµÀ¹ýÃôÖеÄ×÷ÓüõÈõ¡£×îºó£¬Ñо¿Õßͨ¹ýELISA·¢ÏÖCNTN1ˮƽÓëÆøµÀÑ×Ö¢·´Ó¦ÃÜÇÐÏà¹Ø£¬ÎÞÂÛÊǺ¬ÓÐEXOµÄѪÇåºÍ²»º¬EXOµÄѪÇåÖеÄCNTN1ˮƽÔÚÏø´»¼ÕßÖÐÏÔÖøÉý¸ß£¬ÇÒÓëÆøµÀÑ×Ö¢·´Ó¦Ë®Æ½ÕýÏà¹Ø£¨Í¼1F£©¡£
×ÛÉÏ£¬±¾Ñо¿·¢ÏÖÁËÏø´·¢ÉúµÄлúÖÆ£ºÍâ½ç´Ì¼¤¿ÉÒÔ´Ù½øÆøµÀÉÏƤϸ°û·ÖÃÚº¬ÓÐCNTN1µÄÍâÃÚÌ壬ÍâÃÚÌåCNTN1µ°°×ͨ¹ýÓëDCϸ°ûÉÏNotch2ÊÜÌå½áºÏ£¬¼¤»îNotchÐźÅͨ·´Ó¶ø»î»¯DCϸ°û£¬¼ÓÇ¿DCϸ°ûµÄ¿¹Ô³ÊµÝÄÜÁ¦£¬¼Ó¾ç·Î²¿Ñ×Ö¢£¨Í¼1G£©¡£
| °¸Àý¶þ ¸ÉÈÅËØα/βÔö¼ÓÍâÃÚÌåµÄhACE2±í´ï£¬×è¶Ïйڲ¡¶¾¸´Öƺ͸ÐȾ
±¾Ñо¿ÔÚ2021Äê·¢±íÓÚSignal Transduct Target TherÔÓÖ¾£¨IF:18.187£©3¡£Ñо¿ÈËÔ±Ê×ÏÈ·ÖÎöÁËÈËÀ಻ͬϸ°ûϵÖÐѪ¹Ü½ôÕÅËØת»¯Ã¸2£¨hACE2£©µÄ±í´ïÇé¿ö£¬·¢ÏÖhACE2²»½ö¿ÉÒÔÔÚϸ°û±íÃæ±í´ï£¬»¹±í´ïÔÚϸ°û·ÖÃÚµÄÍâÃÚÌåÖУ¨Í¼2A£©¡£
IÐ͸ÉÈÅËØ£¨IFN£©¶Ô¶àÖÖϸ°ûÀàÐ͵IJ¡¶¾¾ßÓйãÆ׿¹²¡¶¾»îÐÔ£¬²¢³äµ±ÊÊÓ¦ÐÔÃâÒßÓ¦´ðµÄ½éÖÊ£¬Ñо¿ÈËÔ±·¢ÏÖIFNα/β´¦ÀíÔö¼ÓÍâÃÚÌåÖÐhACE2µÄ±í´ï£¬¶øÇõÍHrs£¨ESCRTµÄÑÇ»ùÖ®Ò»£¬¿ØÖÆ×ÅÍâÃÚÌå·ÖÃÚ£©ºó£¬IFNα/βÓÕµ¼µÄÍâÃÚÌåhACE2µÄ±í´ïÉϵ÷Êܵ½ÒÖÖÆ£¨Í¼2B£©¡£HEK293Tϸ°ûÓ벡¶¾¹²ÅàÑø¹ý³Ì¼ÓÈëACE2-exo£¨×ªÈ¾hACE2ÖÊÁ£µÄHEK293T·ÖÃÚµÄÍâÃÚÌ壩ºó£¬²¡¶¾¿ÅÁ£½øÈëϸ°ûµÄ¹ý³Ì±»×è¶Ï£¨Í¼2C£©£¬ÓëACE2-exo¹²ÅàÑøºóSARS-CoV-2µÄ¸´ÖÆÒ²Êܵ½ÁËÒÖÖÆ£¨Í¼2D£©£¬ÇÒIFNα/β´¦ÀíµÄÍâÃÚÌåÏà½ÏÓÚδ¾¹ýIFNα/β´¦ÀíµÄÍâÃÚÌåÄÜÏÔÖøÒÖÖÆSARS-CoV-2µÄ¸´ÖÆ£¨Í¼2E£©¡£
ACE2-exo´¦Àí²¡¶¾¸ÐȾµÄСÊóÄ£ÐÍ£¬ELISA¼ì²â·¢ÏÖСÊóѪÇåÖÐÑ×Ö¢Òò×Ó£¨CCL2¡¢CXCL1¡¢IL-1β¡¢IL-6¡¢TNF-ᣩµÄ·ÖÃÚϵ÷£¨Í¼2F£©£¬ÇÒ×éÖ¯²¡ÀíHEȾɫ·¢ÏÖ·ÎÑ×ÓÐËù»º½â£¨Í¼2G£©¡£ÕâЩ·¢ÏÖ½ÒʾÁ˸ÉÈÅËØα/βÔö¼ÓÁËÍâÃÚÌåhACE2µÄ±í´ï£¬ ÌåÍâ¹ý±í´ïhACE2µÄϸ°û·ÖÃÚµÄÍâÃÚÌå»òIFNα/β´¦ÀíµÄϸ°û·ÖÃÚµÄÍâÃÚÌåÄܾºÕùÐÔ×è¶ÏÁ˲¡¶¾µÄ½øÈ룬˵Ã÷ÍâÃÚÌåhACE2¿É×÷ΪDZÔڵĿ¹²¡¶¾Ò©Îï»ò°Ðµã¡£
°¸ÀýÈý »î»¯µÄ¶àÐκ˰×ϸ°ûµÄÍâÃÚÌåµ¼ÖÂÂýÐÔ×èÈûÐԷβ¡
±¾Ñо¿ÔÚ2019Äê·¢±íÓÚCellÔÓÖ¾£¨IF:41.582£©4¡£Ñо¿±íÃ÷ÁËÖÐÐÔÁ£Ï¸°ûµ¯ÐÔµ°°×ø£¨NE£¬neutrophil elastase£©¿ÉÒÔµÖ¿¹α1-¿¹Òȵ°°×ø£¨α1AT£¬alpha1-antitrypsin£©µÄø½â×÷Ó㬴ӶøÆÆ»·Ï¸°ûÍâ»ùÖÊ£¨ECM£¬extracellular matrix£©£¬¼Ó¾ç·ÎʵÖʱäÐΣ¬µ«ÊÇNEµÄ¾ßÌå×÷ÓûúÖƲ¢²»Çå³þ¡£Ñо¿ÈËÔ±ÍƲâNE¿ÉÄÜÒÔÍâÃÚÌåÐÎʽ´æÔÚÈƹýα1AT´Ó¶øµ¼ÖÂÑ×Ö¢ÐԷβ¡¡£
Ê×ÏÈͨ¹ýµ°°×ÖÊ×éѧ¼¼Êõɸѡ·¢ÏÖÁ˻µÄ¶àÐκ˰×ϸ°û£¨polymorphonuclear leukocyte, PMN£©Ïà½ÏÓÚ¾²Ö¹µÄPMN·ÖÃÚµÄÍâÃÚÌå±íÃ溬Óиü¶àµÄNE£¨Í¼3A£©£¬ÇһµÄPMNϸ°ûµÄÍâÃÚÌ壨Act exo£©ÖеÄNEͬÑù¾ßÓп¹Òȵ°°×øα1ATµÄ×÷Óã¨Í¼3B£©¡£Act exo¾ßÓнµ½â½ºÔµ°°×µÄ×÷Ó㬵«ÊÇAct exoºÍNEÒÖÖƼÁÔ¤´¦ÀíÖ®ºó£¬Act exo½µ½â×÷ÓüõÈõ£¬ËµÃ÷Act exoͨ¹ýNE·¢»Ó×÷Óã¨Í¼3C£©£¬¶¯ÎïʵÑéÖ¤Ã÷ÁËAct exo¿ÉÒÔµ¼Ö½¡¿µÐ¡Êó³öÏÖ·ÎÆøÖ×£¨Í¼3D£©¡£
×îºóͨ¹ý³¬ËÙÀëÐÄ·¨·ÖÀëBALF£¨·ÎÅݹàÏ´Òº£©ÖеÄÍâÃÚÌ壬·¢ÏÖCOPD»¼ÕßÏà½ÏÓÚ½¡¿µ¶ÔÕÕµÄBALFÍâÃÚÌåÖк¬Óиü¶àµÄ»îÐÔPMNϸ°û±íÃæ±êÖ¾ÎCD63ºÍCD66b£©£¨Í¼3E£©¡£¶¯ÎïʵÑéÖ¤Ã÷ÁË»¼ÕßBALFÍâÃÚÌå¿ÉÒÔµ¼ÖÂСÊó³öÏÖCOPDÀàËÆÖ¢×´£¨Í¼3F£©¡£
¸ÃÑо¿½Òʾ»î»¯µÄPMNϸ°û·ÖÃÚµÄÍâÃÚÌå±íÃ÷¸²¸ÇÓÐø»îÐÔµÄNEµ°°×£¬ÕâÖÖÍâÃÚÌå±íÃæµÄNE¾ßÓеֿ¹α1-¿¹Òȵ°°×øµÄ×÷Ó㬻µÄPMNϸ°û·ÖÃÚµÄÍâÃÚÌå¿ÉÒÔ½µ½â½ºÔµ°°×£¬ÆÆ»µÏ¸°ûÍâ»ùÖÊ£¬ÒýÆð·ÎÆøÖ×£¨Í¼3G£©¡£
| ½áÂÛÓë×ܽá
´ÓÕ⼸¸ö¾«²ÊµÄ°¸Àý×ܽáÖÐÎÒÃÇ¿ÉÒÔ¿´³ö£¬ÍâÃÚÌåÔÚºôÎüϵͳ¼²²¡µÄ·¢Éú·¢Õ¹ÉϺÁÎÞÒÉÎÊ·¢»ÓÖØÒªµÄ×÷Óá£ÍâÃÚÌåÔڷβ¿Î¢»·¾³µÄ×÷Ó㬿ÉÒÔÊÇÉÏƤϸ°ûÀ´Ô´µÄÍâÃÚÌåÓ°ÏìÃâÒßϸ°û¹¦ÄÜ£¬Ó°ÏìÍâ½ç²¡Ô¾úµÄ×÷Óã¬Ò²¿ÉÒÔÊÇÃâÒßϸ°ûÀ´Ô´µÄÍâÃÚÌå¶ÔÉÏƤϸ°ûµÄ×÷Óá£ÄÇôÔõÑù²ÅÄÜ°ÑÍâÃÚÌåµÄ¼ÛÖµÌåÏÖ³öÀ´ÄØ£¬°Ñ×Ô¼ºµÄÑо¿·¢µ½¸ß·ÖÆÚ¿¯ÉÏÄØ£¿ÉÏÊöµÄÑо¿°¸Àý¸ø³öÁËÒ»¶¨µÄÆôʾ¡£
1£© ¹¦ÄÜ·Ö×ÓµÄɸѡ£º°¸Àý1ºÍ°¸Àý3¾ù²ÉÓÃÁ˵°°×ÖÊ×éѧµÄ·½·¨¼ì²âÍâÃÚÌåÖеŦÄÜ·Ö×Ó£¬Í¨¹ý²îÒìÇé¿öºÍÎÄÏ×µ÷ÑÐËø¶¨¹¦Äܵ°°×¡£°¸Àý2ºÍ°¸Àý3ÓÉÓÚÈ·¶¨µÄµ°°×ÔÚÏà¹Ø¼²²¡ÖеŦÄܺͻúÖÆÑо¿Ïà¶Ô±È½Ï³ÉÊ죬ÊôÓÚÃ÷Ðǵ°°×£¬Èç°¸Àý2ÖеÄhACE2Ó°Ï첡¶¾¸´ÖÆÓë¸ÐȾµÈºÍ°¸Àý3ÖеÄNEÁѽ⽺Ôø¡¢ÆÆ»µÏ¸°ûÍâ»ùÖʵȣ¬¾ùÒѱ»±¨µÀ¡£¶ø°¸ÀýÑо¿Öж¼Ö»ÊÇͨ¹ýÒÆ»¨½Óľ£¬·¢ÏÖÁËÕâЩµ°°×Ö÷Ҫͨ¹ýÍâÃÚÌå´«µÝ×÷Óü´¿É£¬²»ÐèÒª¹ý¶àµÄÍÚ¾òºÍ̽Ë÷£¬»úÖÆ·½ÃæҲûÓÐ×öµÄÌ«É»ù±¾ÉÏÊÇһЩÒÑÖªµÄ¹¦ÄܽáºÏÍâÃÚÌå½øÐÐÑéÖ¤¡£Ð¡±àÌáÐÑ£ºÎÒÃÇÔÚ×ö×éѧɸѡµ°°×·Ö×Óʱ£¬ÖÚ¶àµÄ²îÒì±í´ïµ°°×ÈçºÎÈ·¶¨Ä¿±ê·Ö×Ó£¬³ýÁ˲îÒ챶Êý£¬¾¡Á¿Ñ¡ÔñһЩÃ÷Ðǵ°°×£¬ÕâÑùÓÐÀûÓÚºóÐø»úÖÆÑо¿¡£
2£© ÍâÃÚÌ幦Äܵ°°××÷ÓûúÖƵÄÑéÖ¤£º¶¯Îï»òϸ°ûʵÑéÈ·¶¨¹¦ÄÜ·Ö×ÓµÄ×÷ÓûúÖÆ£¬´Ë²¿·Öͨ³£»á¶ÔÊÜÌåϸ°û²ÉÓÃ×éѧ»òоƬµÄ·½·¨È·¶¨Ïà¹Øϸ°û¹ý³ÌºÍÐźÅͨ·µÄ¸Ä±ä¡£°¸Àý1È·¶¨ÊÜÌåϸ°ûDCµÄÐźÅͨ·Notch£¬¶øÕâÊÇͨ¹ýÎÄÏ×µ÷Ñз¢ÏÖÄ¿±ê·Ö×Ó¿ÉÄÜÓëNotch½áºÏ£¬½ø¶ø½øÐеÄÑéÖ¤¡£µ«ÊǺܶàÇé¿öÏ£¬ÕâÖÖÎÄÏ×µ÷ÑеÄÊÖ¶ÎÍùÍùÈÝÒ×̤¿Õ¡£Èç¹ûÔÚÕâ¸ö»·½Ú²ÉÓÃk8¿·¢(Öйú)ÌṩµÄÐźÅͨ·Á×Ëữ¿¹ÌåоƬ¼¼Êõ½øÐÐÊÜÌåϸ°ûÐźÅͨ·µÄɸѡµÄ»°£¬²»½öʡʱʡÁ¦£¬Ò²ÔÚÒ»¶¨³Ì¶ÈÉϸøÏÂÓλúÖÆÑо¿±£Á˸öµ×¡£
3£© ¹ØÓÚºôÎüϵͳ¼²²¡£¬ÒòΪÓëÆøµÀÑ×Ö¢ÃÜÇÐÏà¹Ø£¬ÎÒÃÇÉÙ²»Á˼ì²âÑ×Ö¢Òò×ÓµÄˮƽ£¬Èç°¸Àý1ºÍ°¸Àý2£¬¿ÉÒÔÑ¡ÔñELISAµÄ·½·¨£¬µ«ÊÇÕë¶Ô¶à¸öÑù±¾£¬¶àÖÖϸ°ûÒò×Ó£¬ELISA²»ÊÇÒ»¸ö×î¼ÑµÄÑ¡Ôñ¡£k8¿·¢(Öйú)ÓµÓГ¸ßͨÁ¿¿¹ÌåоƬ”¡¢“LuminexÒºÏàÐü¸¡Ð¾Æ¬”¡¢µ¥·Ö×Ó¸ßÃôSimoa¼¼Êõ”Èý¸öϸ°ûÒò×ӓһվʽ”·þÎñƽ̨£¬Èýƽ̨¸÷¾ßÓÅÊÆ£¬¾¹ýk8¿·¢(Öйú)Óлú×éºÏ£¬¿ÉÂú×ãϸ°ûÒò×Ó±êÖ¾ÎïÈ«·½Î»ÐèÇó¡£
Õë¶ÔÍâÃÚÌåµÄ×÷ÓûúÖÆÑо¿£¬k8¿·¢(Öйú)ÍâÃÚÌå·þÎñƽ̨ÌṩÍ걸µÄ¼¼Êõ¼ì²â·þÎñ£¬°üÀ¨·á¸»¶àÑùµÄÍâÃÚÌåµÄÌáÈ¡¼°¼ø¶¨·½·¨¡¢ÍâÃÚÌåÌåÄÚÍâʾ×Ù¡¢ÍâÃÚÌ幦ÄÜ·Ö×Óɸѡ¼°ÑéÖ¤¡¢ÍâÃÚÌå»úÖÆÑо¿³£ÓõÄ×éѧ»òоƬ¼¼Êõ·þÎñµÈ¡£
·á¸»È«ÃæµÄÍâÃÚÌ幦ÄÜÑо¿ÊÖ¶ÎÈ«¶¼ÔÚk8¿·¢(Öйú)µÄÎäÆ÷¿âÖУ¨ºìɫΪk8¿·¢(Öйú)ÌØÉ«·þÎñ£©£¬»¶Óµç»°´¹Ñ¯£º400-869-2936¡£
| Ïà¹ØÎÄÏ×
[1] Nana-Sinkam S P, Acunzo M, Croce C M, et al. Extracellular Vesicle Biology in the Pathogenesis of Lung Disease. [J]. American Journal of Respiratory & Critical Care Medicine, 2017: rccm. 201612-2457PP.
[2] Md M Z, Yu Q, Md W T, et al. Epithelial exosomal contactin-1 promotes monocyte-derived dendritic cells-dominant T cell responses in asthma. [J]. Journal of Allergy and Clinical Immunology. 2021, May 3: S0091-6749(21)00720-X.
[3] Junsong Zhang, Feng Huang, et al. The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blockingthe virus entry. [J]. Signal Transduct Target Ther. 2021 May 12;6(1):189.
[4] Genschmer K R, Russell D W, Lal C, et al. Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung. [J]. Cell, 2019, 176(1-2):113-126.e15.
µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã
µç»°£º400-869-2936£¬021-33968791
ÓÊÏ䣺support@wayenbiotech.com
´«Õ棺021-33938792
QQ£º2120485725
Õ½ÂÔºÏ×÷
Õ½ÂÔºÏ×÷
| Full Moon | RayBiotech | CDI | IZON | Bio-Rad | R&D Systems | IsoPlexis | ÄÏÄ£ÉúÎï | Å·Ò×ÉúÎï | ÆäÃ÷ÐÅÏ¢ | ÃÀ¼ªÉúÎï | ÂóÌØ»æÆ× |
Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿·¢(Öйú)Ô´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£